Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 10:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 38 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Bone Marrow Derived MSCs Clear all
Recruiting Phase 2 Interventional

Efficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells

NCT05705024
View directory record Official record
Conditions
Corneal Ulcer
Interventions
Mesenchymal Stromal Cells, Control Solution
Biological · Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 8, 2026, 10:51 PM EDT
Terminated Phase 1 Interventional

Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease

NCT04328714
View directory record Official record
Conditions
Acute Leukemia, Myelodysplastic Syndromes
Interventions
Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells
Drug
Lead sponsor
Edwin Horwitz
Other
Eligibility
1 Year and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 8, 2026, 10:51 PM EDT
Completed Phase 1 Interventional Results available

MSC in Patients With Xerostomia Post XRT in Head and Neck Cancer

NCT04489732
View directory record Official record
Conditions
Xerostomia Following Radiotherapy
Interventions
Autologous bone-marrow derived, interferon gamma stimulated mesenchymal stromal cells
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 90 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 8, 2026, 10:51 PM EDT
Completed Phase 1 Interventional

Bone Marrow Derived Mesenchymal Stem Cells in Improving Heart Function in Patients With Heart Failure Caused by Anthracyclines

NCT02408432
View directory record Official record
Conditions
Cardiomyopathy, Heart Failure
Interventions
Laboratory Biomarker Analysis, Standard of Care, Mesenchymal Stem Cell Transplantation
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Sep 8, 2026, 10:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Tolerability Study of Allogeneic Mesenchymal Stem Cell Infusion in Adults With Cystic Fibrosis

NCT02866721
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Mesenchymal Stem Cells
Biological
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Sep 8, 2026, 10:51 PM EDT
Not listed Phase 1Phase 2 Interventional

Mesenchymal Stem Cell Therapy for Knee Osteoarthritis

NCT05288725
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Bone Marrow Derived MSCs, Corticosteroid, Bone Marrow Aspirate
Biological · Drug · Device
Lead sponsor
Next Generation Regenerative Medicine LLC
Network
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Chesterfield, Missouri • Steubenville, Ohio • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 20, 2022 · Synced Sep 8, 2026, 10:51 PM EDT
Completed Phase 2 Interventional Results available

Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs

NCT00957931
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia, Diamond-Blackfan Anemia
Interventions
Bone marrow transplantation, Mesenchymal Stromal Cells
Procedure · Biological
Lead sponsor
Stanford University
Other
Eligibility
1 Year to 25 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Birmingham, Alabama • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 5, 2018 · Synced Sep 8, 2026, 10:51 PM EDT
Terminated Phase 1Phase 2 Interventional

Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC)

NCT04543994
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Remestemcel-L, Placebo
Drug · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 8, 2026, 10:51 PM EDT
Completed Phase 2 Interventional Results available

Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis

NCT03355365
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Intrathecal MSC-NP injection, Intrathecal saline injection
Biological · Other
Lead sponsor
Tisch Multiple Sclerosis Research Center of New York
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Sep 8, 2026, 10:51 PM EDT
Active, not recruiting Phase 2 Interventional

Allogeneic BM-MSCs in Patients With Painful Lumbar Facet Arthropathy

NCT06001853
View directory record Official record
Conditions
Facet-Mediated Low Back Pain, Lumbar Facet Joint Osteoarthritis
Interventions
BM-MSC injection, DSMO Injection
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 8, 2026, 10:51 PM EDT
Completed Phase 1 Interventional

Allogeneic Bone Marrow Mesenchymal Stem Cells for Patients With Interstitial Lung Disease (ILD) & Connective Tissue Disorders (CTD)

NCT03929120
View directory record Official record
Conditions
Interstitial Lung Disease, Connective Tissue Diseases
Interventions
Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs)
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Sep 8, 2026, 10:51 PM EDT
Withdrawn Phase 1 Interventional

Stem Cells for the Treatment of Pouchitis

NCT05578508
View directory record Official record
Conditions
Pouchitis, Crohn's Disease, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Pouch, Ileal
Interventions
Mesenchymal Stem Cells (MSCs)
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 8, 2026, 10:51 PM EDT
Terminated Phase 1Phase 2 Interventional

Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's Colitis

NCT04548583
View directory record Official record
Conditions
Crohn Colitis
Interventions
Remestemcel-L, Placebo
Drug · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 8, 2026, 10:51 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of REcycled CartiLage Auto/Allo IMplantation to Treat and Repair Focal Hip Cartilage Defects

NCT05553132
View directory record Official record
Conditions
Cartilage Defect
Interventions
Autologous Chondrocytes in their Pericellular Matrix (Chondrons) Coimplanted with Allogeneic Adipose-Derived Mesenchymal Stromal Cells (AMSCs) in a Fibrin Glue Carrier
Combination Product
Lead sponsor
Daniel B. F. Saris
Other
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 8, 2026, 10:51 PM EDT
Recruiting Phase 1 Interventional

Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression

NCT03522545
View directory record Official record
Conditions
Treatment-resistant Bipolar Depression
Interventions
Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs), Placebo
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2025 · Synced Sep 8, 2026, 10:51 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Allogeneic Human Bone Marrow Derived Mesenchymal Stem Cells in Localized Prostate Cancer

NCT01983709
View directory record Official record
Conditions
Prostate Cancer
Interventions
Allogeneic Human Mesenchymal Stem Cells
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2018 · Synced Sep 8, 2026, 10:51 PM EDT
Recruiting Phase 1 Interventional

Phase 1 Study of VELGRAFT, a Living Cellular Construct, in the Management of Chronic Diabetic Foot Ulcers Which Have Attained Granulation Tissue

NCT07498218
View directory record Official record
Conditions
Diabetic Foot Ulcer (DFU), Granulation of Chronic Diabetic Wounds
Interventions
an allogenic cell-based product, containing living human bone marrow-derived mesenchymal stem cells (MSCs) and MSCs differentiated into adipocytes on a porous chitosan-gelatin matrix, Standard of Care of Diabetic Foot Ulcers
Drug · Other
Lead sponsor
Ayu, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 8, 2026, 10:51 PM EDT
Recruiting Early Phase 1 Interventional

Safety and Efficacy of Mesenchymal Stem Cells Associated With Chronic Pancreatitis Pain

NCT06205342
View directory record Official record
Conditions
Chronic Pancreatitis, Chronic Pain
Interventions
Mesenchymal Stem Cells, Other: Placebo
Drug · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 8, 2026, 10:51 PM EDT
Recruiting Phase 1 Interventional

Novel Cellular Therapy for the Treatment of Pain Associated With Chronic Pancreatitis

NCT05925036
View directory record Official record
Conditions
Chronic Pancreatitis, Chronic Pain
Interventions
Mesenchymal stem cells, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 8, 2026, 10:51 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Infusion of Umbilical Cord Versus Bone Marrow Derived Mesenchymal Stem Cells to Evaluate Cytokine Suppression.

NCT03059355
View directory record Official record
Conditions
Endothelial Dysfunction, Metabolic Syndrome, Chronic Inflammation
Interventions
UCMSCs, BMMSCs, Placebo
Biological · Other
Lead sponsor
Joshua M Hare
Other
Eligibility
21 Years to 95 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 8, 2026, 10:51 PM EDT
Not listed Phase 1 Interventional

Study to Evaluate Hepatic Artery Injection of Autologous Human Bone Marrow-Derived MSCs in Patients With Alcoholic LC

NCT03838250
View directory record Official record
Conditions
Alcoholic Liver Cirrhosis
Interventions
Cellgram™ (Bone marrow-derived MSCs)
Biological
Lead sponsor
Pharmicell Co., Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 8, 2026, 10:51 PM EDT
Completed Phase 2 Interventional Results available

MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs

NCT02582775
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
Thymoglobulin, Cyclophosphamide, Fludarabine, Total Body Irradiation, Bone marrow infusion, Tacrolimus, Mycophenolate Mofetil, Donor mesenchymal stem cell infusions, Busulfan
Drug · Radiation · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 25 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 8, 2026, 10:51 PM EDT
Recruiting Phase 1 Interventional

Autologous Mesenchymal Stromal Cells and Islet Co-transplantation in TP-IAT

NCT05095532
View directory record Official record
Conditions
Chronic Pancreatitis, Mesenchymal Stem Cells
Interventions
Bone marrow-derived mesenchymal stem cells, Placebo
Biological · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 8, 2026, 10:51 PM EDT
Completed Phase 2 Interventional Results available

Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson's Disease

NCT04506073
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Mesenchymal Stem Cells, Placebo
Drug
Lead sponsor
Mya Schiess
Other
Eligibility
50 Years to 79 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 8, 2026, 10:51 PM EDT